UnicoCell Biomed Co., Ltd. (TPE:6794)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
65.10
0.00 (0.00%)
May 7, 2025, 1:30 PM CST
-21.57%
Market Cap 3.95B
Revenue (ttm) 31.88M
Net Income (ttm) -93.07M
Shares Out 60.61M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,001
Average Volume 13,658
Open 64.50
Previous Close 65.10
Day's Range 64.00 - 65.40
52-Week Range 62.50 - 88.00
Beta -0.32
RSI 41.31
Earnings Date May 14, 2025

About UnicoCell Biomed

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. It develops ELIXCYTE, which is in Phase 2 clinical trials for the treatment of osteoarthritis and chronic kidney disease. The company offers UnicoVial, a cryotube and drug container for cell therapy products, as well as provides testing services. UnicoCell Biomed Co., Ltd. is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Yi-Pei Hung
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6794
Full Company Profile

Financial Performance

In 2024, UnicoCell Biomed's revenue was 31.88 million, an increase of 29.66% compared to the previous year's 24.59 million. Losses were -93.07 million, 10.7% more than in 2023.

Financial Statements

News

There is no news available yet.